Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,474 across all filing types
Latest filing 2020-01-02 Share Issue/Capital Cha…
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on movements in Securities for the month ended 31 December 2019
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 31/12/2019, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorised share capital, issued share capital, share options, warrants, convertibles, and other share capital changes. The content is focused on share capital changes and movements rather than financial performance, earnings, or management commentary. It is a regulatory filing reporting share capital movements for a specific month, typical of a Major Shareholding Notification or Share Issue/Capital Change. However, since it covers detailed monthly movements in securities and share capital, it aligns best with Share Issue/Capital Change filings. The document length is over 13,000 characters and contains substantive data, so it is not a mere announcement or report publication notice.
2020-01-02 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2019
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 31/12/2019 and submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized and issued share capital, share options, warrants, convertibles, and other share-related transactions during the month. It includes confirmations by the company secretary regarding compliance with listing rules and legal requirements. The content focuses on share capital changes and related confirmations rather than financial performance, earnings, or management commentary. It is a regulatory filing reporting monthly share capital movements and confirmations to the exchange, not a full financial report or announcement of voting results. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance document that does not fit other specific categories.
2020-01-02 English
Next Day Disclosure Return
Share Issue/Capital Change Classification · 95% confidence The document is a Next Day Disclosure Return for a Main Board listed issuer, Ascletis Pharma Inc., detailing changes in issued share capital and share buybacks. It includes specific data on share repurchases, issued shares, and confirmations related to compliance with listing rules. The content focuses on reporting share capital changes and repurchase activities, which aligns with announcements regarding share issues or capital changes. There is no indication of a full financial report, audit, earnings release, or management discussion. The document is regulatory in nature but specifically about share capital changes and buybacks, fitting the category of Share Issue/Capital Change announcements rather than a general regulatory filing or report publication announcement. The document length (8889 characters) supports it being a detailed disclosure rather than a brief announcement. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2019-12-31 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is a Next Day Disclosure Return for a Main Board listed issuer, Ascletis Pharma Inc., detailing changes in issued share capital and share buybacks. It includes specific data on shares issued, repurchased, and cancelled, along with confirmations related to compliance with listing rules. The document references rules from the Hong Kong Stock Exchange Listing Rules and provides detailed transactional data on share repurchases. This type of document is a regulatory disclosure about share capital changes and share buybacks, not a full financial report or earnings release. It fits the definition of a Transaction in Own Shares (POS) filing, which reports company buybacks or sales of its own shares. The document length (9026 characters) and content confirm it is a detailed disclosure rather than a brief announcement or certification. Therefore, the correct classification is POS.
2019-12-06 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 95% confidence The document is a disclosure return related to changes in issued share capital and share buybacks by Ascletis Pharma Inc., submitted to the Hong Kong Stock Exchange. It details share repurchases, issued shares, prices, and confirmations of compliance with listing rules. The content focuses on reporting share repurchase transactions and capital changes rather than financial results, management commentary, or regulatory certifications. It is not a full financial report, earnings release, or management discussion. The document fits the description of a Transaction in Own Shares (POS) filing, which reports company buybacks or sales of its own shares. The length and detail confirm it is the actual report, not just an announcement or certification.
2019-12-05 English
Next Day Disclosure Return
Share Issue/Capital Change Classification · 95% confidence The document is a Next Day Disclosure Return for a Main Board listed issuer, Ascletis Pharma Inc., detailing changes in issued share capital and share buybacks. It includes specific data on share repurchases, issued shares, prices, and confirmations related to compliance with listing rules. The content focuses on reporting share capital changes and repurchase activities, which aligns with announcements regarding share issues or capital changes. The document is not a full financial report, audit, or earnings release, nor is it a meeting presentation or voting result. It is a regulatory disclosure about share capital changes and buybacks, fitting the category of Share Issue/Capital Change (SHA). The document length (8639 characters) and detailed data confirm it is a substantive disclosure, not merely an announcement of a report publication or a certification. Therefore, the appropriate classification is SHA with high confidence.
2019-12-04 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.